Drugs / Wharton's Jelly Mesenchymal Stem Cells
Wharton's Jelly Mesenchymal Stem Cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06981338 | Sep 2025 → Mar 2026 overdue | spinal cord injury | Institut Guttmann | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06304025 | Jun 2024 → Jun 2025 | acute graft versus host disease | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | Unknown | No outcome recorded |
| Phase 1/2 | NCT04651855 | Dec 2020 → Mar 2022 | amyotrophic lateral sclerosis | Polski Bank Komorek Macierzystych JSC (PBKM) | Unknown | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04625738 | Nov 2020 → May 2021 | adult acute respiratory distress syndrome | Central Hospital, Nancy, France | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton's jelly mesenchymal stem cells | “The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)” NCT04651855 ↗ |
| Known as | Wharton Jelly-derived Mesenchymal Stromal Cells | “Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by the SARS-CoV-2 infection through pro-angiogenic effects, lung...” PMID 37706025 ↗ Aug 2023 |
| Known as | Wharton's Jelly MSCs | “Either Wharton's Jelly MSCs in a solution of albumin 4% (40% of final volume), NaCl 0,9% (50% of the final volume) et ACD formule A (10% of the final volume)” NCT04625738 ↗ |
| Known as | WJMSCs | “Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by the SARS-CoV-2 infection through pro-angiogenic effects, lung...” PMID 37706025 ↗ Aug 20232“The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) on the Immune System of Patients With Amyotrophic Lateral Sclerosis (ALS)” NCT04651855 ↗ “Wharton's jelly mesenchymal stem cells (WJ-MSCs)” NCT06304025 ↗ |
| Modality | Cell therapy | “Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs)” PMID 37706025 ↗ Aug 2023 |
| Route | Intravenous | “1 intravenous infusion of 1 × 106 WJ-MSCs/kg” PMID 37706025 ↗ Aug 2023 |